J. Witte

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

N. Brünner, J. Foekens, J. Klijn, 2001, British Journal of Cancer.

Angiotensin II Receptor–Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179

H. Drexler, M. Walden, J. Witte, 2002, Circulation research.

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

J. Foekens, J. Klijn, C. Sweep, 1999, British Journal of Cancer.

Anti-Inflammatory Therapy in Coronary Artery Disease omparative Effects of AT 1-Antagonism nd Angiotensin-Converting Enzyme Inhibition n Markers of Inflammation and Platelet ggregation in Patients With Coronary Artery Disease

H. Drexler, J. Witte, E. Schwedhelm, 2016 .

Quality control in quantitation of components of the plasminogen activator system in tumour extracts

C. Sweep, A. Geurts-Moespot, J. Witte, 1996 .

Electrophoretic light scattering studies on the interaction of fibrinogen with resting and activated human platelets

J. Witte, D. Gabriel, X. Li, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Effects of physical stress and pharmacologically induced coronary dilation on myocardial and non-myocardial 201Thallium-uptake

J. Witte, B. Strauer, U. Büll, 2004, European Journal of Nuclear Medicine.

, Boris of Losartan : Role of the Active Metabolite EXP 3179 Independent Antiinflammatory and Antiaggregatory Properties − Angiotensin II Receptor

H. Drexler, M. Walden, J. Witte, 2002 .

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.

H. Drexler, J. Witte, E. Schwedhelm, 2004, Journal of the American College of Cardiology.